The study was conducted in partnership with the International Centre for Diarrhoeal Disease Research, Bangladesh
Making headway towards providing the developing nations an affordable and easy-to-use Heat Stable Rotavirus Vaccine (HSRV), Hilleman Laboratories, a joint-venture between Merck Sharp & Dohme (MSD) and the Wellcome Trust, announced the successful completion of Phase I/II clinical trial of its oral vaccine against the deadly Rotavirus disease. The study was conducted in partnership with the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b).
The results of the clinical trials were presented at the Vaccines for Enteric Disease Conference 2017, held in Albufeira, Portugal.
Sharing results of the study, Dr K Zaman, Senior Scientist and Epidemiologist at icddr,b said, “Safety data have demonstrated that administration of HSRV, when compared with placebo, did not result in an increased reporting of solicited AEs in the adult cohort. In infants when administered as three-dose primary series, HSRV had a safety profile similar to RotaTeq in terms of frequency, severity, and causality of solicited adverse effect. Immunogenicity assessment was found to be comparable between the HSRV and RotaTeq in infants. The percentage of infants exhibiting a three-fold rise in serum anti-rotavirus IgA at 1 month post-dose three administration from baseline in HSRV group was 88 per cent. The percentage of infants who had a similar increase in the RotaTeq group was 84 per cent. In addition, HSRV elicited comparable Geometric Mean Titre relative to RotaTeq, 1 month after completion of 3-dose vaccination schedule. Based on the encouraging results obtained in this study, HSRV will be further evaluated in immunogenicity and safety studies in infants.
Talking about the accomplishment, Dr Davinder Gill, CEO Hilleman Laboratories said, “Rotavirus is the leading cause of severe diarrhoea and related deaths in children less than five years worldwide. First-generation Rotavirus vaccines possess thermostability profiles that may not meet storage requirements in developing countries, highlighting the need for heat stable vaccines. Considering the urgent need for effective and affordable Rotavirus vaccines, we would like to accelerate development of our simplified, easy-to-use, heat stable vaccine.”
After successful completion of the preclinical animal studies and obtaining regulatory clearance for human studies, Hilleman Laboratories had initiated a clinical study in April 2016, to establish proof-of-concept for its heat stable Rotavirus vaccine. The vaccine is aimed at allowing greater temperature stability and less reliance on exact storage timing and refrigeration.